Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Blueprint Medicines Corp (NQ: BPMC ) 90.70 +3.19 (+3.65%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Blueprint Medicines Corp < Previous 1 2 3 4 5 6 Next > Where Blueprint Medicines Stands With Analysts April 19, 2023 Via Benzinga 16 Analysts Have This to Say About Blueprint Medicines March 30, 2023 Via Benzinga FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study March 29, 2023 Via Benzinga The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector March 15, 2023 To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. Via InvestorPlace Where Blueprint Medicines Stands With Analysts February 27, 2023 Via Benzinga Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients February 27, 2023 Via Benzinga Earnings Scheduled For February 16, 2023 February 16, 2023 Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... Via Benzinga Earnings Preview For Blueprint Medicines February 15, 2023 Via Benzinga Analyst Ratings for Blueprint Medicines January 23, 2023 Via Benzinga Where Blueprint Medicines Stands With Analysts December 12, 2022 Via Benzinga 9 Analysts Have This to Say About Blueprint Medicines November 02, 2022 Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: Via Benzinga Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines February 23, 2023 Via Benzinga FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study February 10, 2023 Via Benzinga Blueprint Medicines's Return On Capital Employed Overview November 07, 2022 According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16... Via Benzinga Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake November 02, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 November 02, 2022 Upgrades Via Benzinga Recap: Blueprint Medicines Q3 Earnings November 01, 2022 Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 December 14, 2022 Via Benzinga Where Blueprint Medicines Stands With Analysts September 09, 2022 Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: Via Benzinga Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says August 18, 2022 Via Benzinga Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday November 02, 2022 Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market... Via Benzinga NASDAQ:BPMC Investor Notice: Investigation over Potential Wrongdoing at Blueprint Medicines Corporation October 12, 2022 San Diego, CA -- (SBWIRE) -- 10/12/2022 -- Certain directors of Blueprint Medicines Corporation are under investigation over potential breaches of fiduciary duties. Via SBWire Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 September 14, 2022 Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... Via Benzinga ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC September 05, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws August 30, 2022 San Diego, CA -- (SBWIRE) -- 08/30/2022 -- Blueprint Medicines Corporation is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire What 14 Analyst Ratings Have To Say About Blueprint Medicines August 22, 2022 Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Via Benzinga INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm August 19, 2022 From The Schall Law Firm Via Business Wire Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday August 22, 2022 Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. Via Benzinga INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm August 18, 2022 From The Schall Law Firm Via Business Wire This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday August 18, 2022 Gainers Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
